J&J Plans €1.75B Offer For Dutch Vaccine Developer
Johnson & Johnson is in advanced talks to buy the bulk of vaccine developer Crucell NV for €1.75 billion ($2.29 billion) through an all-cash public offer that would give the U.S....To view the full article, register now.
Already a subscriber? Click here to view full article